FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1999489097> ?p ?o ?g. }

• W1999489097 endingPage "S113" @default.
• W1999489097 startingPage "S112" @default.
• W1999489097 abstract "Purpose/ObjectivesA Phase I trial was conducted to determine the maximum tolerated dose (MTD) of the combination of concurrent paclitaxel (fixed dose of 30 mg/m2 twice a week during radiotherapy) and definitive radiation therapy (RT) in patients with locally advanced prostate cancer (LAPC).Materials/MethodsEligible patients were LAPC carriers, defined as clinical stage T2/T3 with Gleason score >7 and/or PSA >10 ng/ml; and/or pathologic stage TxN1. All patients underwent hormonal ablation for a total of 9 months which was initiated at least 3 months prior to the beginning of RT. Treatment consisted of daily three-dimensional conformal RT with concurrent paclitaxel given twice weekly at a dose of 30 mg/m2. Radiation was delivered at 1.8 Gy per fraction and the total dose was escalated as it follows: 63 Gy, 66.6 Gy, 70.2 Gy, and 73.8 Gy. The latter dose was pre-determined as the last dose level for MTD, since 73.8 Gy is the standard dose for hormonally ablated LABC treated with radiation alone. Radiation technique included treatment of the whole pelvis to 39.6 Gy using a four field box with a consecutive boost to the prostate and seminal vesicles using a six field conformal technique. No intensity modulated RT was used in this trial.ResultsBetween January 2000 and October, 2006, 22 patients were enrolled in this IRB-approved combined modality protocol. Median age was 59 (range 48–72) and median PSA was 22.4 (range, 2.8–113). Clinical T-stages were: T1 (n = 3), T2 (n = 8), and T3 (n = 11) Five patients were pN1. One patient received prescribed RT but did not receive the first 2 doses of chemotherapy and is included in the analysis. All other patients received the prescribed treatment.Initially the study was designed to treat whole pelvis followed by the boost to the prostate. The median clinical target volume for the boost was 70 cc (range, 29–99). No grade 3 toxicities occurred at the first dose level of 63 Gy with concurrent chemotherapy. Grade 1–2 toxicities occurred at each dose level and consisted of diarrhea in 7 (32%) patients and urinary frequency in 7 (32%).Grade 3 diarrhea was observed in 3 patients at a dose of 66.6 Gy. The protocol was then amended to first treat the prostate boost volume, followed by treatment of the whole pelvis to 39.6 Gy. With this sequencing, no grade 3 toxicities were observed at the 70.2 Gy dose level. One patient experienced grade 3 diarrhea at 73.8 Gy an additional 5 patients were treated to 73.8 Gy without grade 3 toxicity, establishing the MTD for combined paclitaxel and RT at 73.8 Gy.At a median follow up of 27 months (range, 1 to 69 months), 21 of 22 (95%) patients are alive. Six of 22 (27%) have had recurrence: one local, three distant, and two biochemical failures without clinical evidence of disease.ConclusionsConcurrent bi-weekly paclitaxel (30 mg/m2) with RT is feasible and the MTD is 73.8 Gy. Early clinical results are promising for this subset of patients with a dire prognosis. Purpose/ObjectivesA Phase I trial was conducted to determine the maximum tolerated dose (MTD) of the combination of concurrent paclitaxel (fixed dose of 30 mg/m2 twice a week during radiotherapy) and definitive radiation therapy (RT) in patients with locally advanced prostate cancer (LAPC). A Phase I trial was conducted to determine the maximum tolerated dose (MTD) of the combination of concurrent paclitaxel (fixed dose of 30 mg/m2 twice a week during radiotherapy) and definitive radiation therapy (RT) in patients with locally advanced prostate cancer (LAPC). Materials/MethodsEligible patients were LAPC carriers, defined as clinical stage T2/T3 with Gleason score >7 and/or PSA >10 ng/ml; and/or pathologic stage TxN1. All patients underwent hormonal ablation for a total of 9 months which was initiated at least 3 months prior to the beginning of RT. Treatment consisted of daily three-dimensional conformal RT with concurrent paclitaxel given twice weekly at a dose of 30 mg/m2. Radiation was delivered at 1.8 Gy per fraction and the total dose was escalated as it follows: 63 Gy, 66.6 Gy, 70.2 Gy, and 73.8 Gy. The latter dose was pre-determined as the last dose level for MTD, since 73.8 Gy is the standard dose for hormonally ablated LABC treated with radiation alone. Radiation technique included treatment of the whole pelvis to 39.6 Gy using a four field box with a consecutive boost to the prostate and seminal vesicles using a six field conformal technique. No intensity modulated RT was used in this trial. Eligible patients were LAPC carriers, defined as clinical stage T2/T3 with Gleason score >7 and/or PSA >10 ng/ml; and/or pathologic stage TxN1. All patients underwent hormonal ablation for a total of 9 months which was initiated at least 3 months prior to the beginning of RT. Treatment consisted of daily three-dimensional conformal RT with concurrent paclitaxel given twice weekly at a dose of 30 mg/m2. Radiation was delivered at 1.8 Gy per fraction and the total dose was escalated as it follows: 63 Gy, 66.6 Gy, 70.2 Gy, and 73.8 Gy. The latter dose was pre-determined as the last dose level for MTD, since 73.8 Gy is the standard dose for hormonally ablated LABC treated with radiation alone. Radiation technique included treatment of the whole pelvis to 39.6 Gy using a four field box with a consecutive boost to the prostate and seminal vesicles using a six field conformal technique. No intensity modulated RT was used in this trial. ResultsBetween January 2000 and October, 2006, 22 patients were enrolled in this IRB-approved combined modality protocol. Median age was 59 (range 48–72) and median PSA was 22.4 (range, 2.8–113). Clinical T-stages were: T1 (n = 3), T2 (n = 8), and T3 (n = 11) Five patients were pN1. One patient received prescribed RT but did not receive the first 2 doses of chemotherapy and is included in the analysis. All other patients received the prescribed treatment.Initially the study was designed to treat whole pelvis followed by the boost to the prostate. The median clinical target volume for the boost was 70 cc (range, 29–99). No grade 3 toxicities occurred at the first dose level of 63 Gy with concurrent chemotherapy. Grade 1–2 toxicities occurred at each dose level and consisted of diarrhea in 7 (32%) patients and urinary frequency in 7 (32%).Grade 3 diarrhea was observed in 3 patients at a dose of 66.6 Gy. The protocol was then amended to first treat the prostate boost volume, followed by treatment of the whole pelvis to 39.6 Gy. With this sequencing, no grade 3 toxicities were observed at the 70.2 Gy dose level. One patient experienced grade 3 diarrhea at 73.8 Gy an additional 5 patients were treated to 73.8 Gy without grade 3 toxicity, establishing the MTD for combined paclitaxel and RT at 73.8 Gy.At a median follow up of 27 months (range, 1 to 69 months), 21 of 22 (95%) patients are alive. Six of 22 (27%) have had recurrence: one local, three distant, and two biochemical failures without clinical evidence of disease. Between January 2000 and October, 2006, 22 patients were enrolled in this IRB-approved combined modality protocol. Median age was 59 (range 48–72) and median PSA was 22.4 (range, 2.8–113). Clinical T-stages were: T1 (n = 3), T2 (n = 8), and T3 (n = 11) Five patients were pN1. One patient received prescribed RT but did not receive the first 2 doses of chemotherapy and is included in the analysis. All other patients received the prescribed treatment. Initially the study was designed to treat whole pelvis followed by the boost to the prostate. The median clinical target volume for the boost was 70 cc (range, 29–99). No grade 3 toxicities occurred at the first dose level of 63 Gy with concurrent chemotherapy. Grade 1–2 toxicities occurred at each dose level and consisted of diarrhea in 7 (32%) patients and urinary frequency in 7 (32%). Grade 3 diarrhea was observed in 3 patients at a dose of 66.6 Gy. The protocol was then amended to first treat the prostate boost volume, followed by treatment of the whole pelvis to 39.6 Gy. With this sequencing, no grade 3 toxicities were observed at the 70.2 Gy dose level. One patient experienced grade 3 diarrhea at 73.8 Gy an additional 5 patients were treated to 73.8 Gy without grade 3 toxicity, establishing the MTD for combined paclitaxel and RT at 73.8 Gy. At a median follow up of 27 months (range, 1 to 69 months), 21 of 22 (95%) patients are alive. Six of 22 (27%) have had recurrence: one local, three distant, and two biochemical failures without clinical evidence of disease. ConclusionsConcurrent bi-weekly paclitaxel (30 mg/m2) with RT is feasible and the MTD is 73.8 Gy. Early clinical results are promising for this subset of patients with a dire prognosis. Concurrent bi-weekly paclitaxel (30 mg/m2) with RT is feasible and the MTD is 73.8 Gy. Early clinical results are promising for this subset of patients with a dire prognosis." @default.
• W1999489097 created "2016-06-24" @default.
• W1999489097 creator A5011556876 @default.
• W1999489097 creator A5037701284 @default.
• W1999489097 creator A5048709555 @default.
• W1999489097 creator A5060202182 @default.
• W1999489097 creator A5062397416 @default.
• W1999489097 date "2007-11-01" @default.
• W1999489097 modified "2023-09-27" @default.
• W1999489097 title "Phase I Study of Bi-weekly Paclitaxel and Definitive Radiation in Androgen Ablated Locally Advanced Prostate Cancer" @default.
• W1999489097 doi "https://doi.org/10.1016/j.ijrobp.2007.07.208" @default.
• W1999489097 hasPublicationYear "2007" @default.
• W1999489097 type Work @default.
• W1999489097 sameAs 1999489097 @default.
• W1999489097 citedByCount "0" @default.
• W1999489097 crossrefType "journal-article" @default.
• W1999489097 hasAuthorship W1999489097A5011556876 @default.
• W1999489097 hasAuthorship W1999489097A5037701284 @default.
• W1999489097 hasAuthorship W1999489097A5048709555 @default.
• W1999489097 hasAuthorship W1999489097A5060202182 @default.
• W1999489097 hasAuthorship W1999489097A5062397416 @default.
• W1999489097 hasBestOaLocation W19994890971 @default.
• W1999489097 hasConcept C121608353 @default.
• W1999489097 hasConcept C126322002 @default.
• W1999489097 hasConcept C143998085 @default.
• W1999489097 hasConcept C2776235491 @default.
• W1999489097 hasConcept C2777292972 @default.
• W1999489097 hasConcept C2777911890 @default.
• W1999489097 hasConcept C2780192828 @default.
• W1999489097 hasConcept C71315377 @default.
• W1999489097 hasConcept C71924100 @default.
• W1999489097 hasConceptScore W1999489097C121608353 @default.
• W1999489097 hasConceptScore W1999489097C126322002 @default.
• W1999489097 hasConceptScore W1999489097C143998085 @default.
• W1999489097 hasConceptScore W1999489097C2776235491 @default.
• W1999489097 hasConceptScore W1999489097C2777292972 @default.
• W1999489097 hasConceptScore W1999489097C2777911890 @default.
• W1999489097 hasConceptScore W1999489097C2780192828 @default.
• W1999489097 hasConceptScore W1999489097C71315377 @default.
• W1999489097 hasConceptScore W1999489097C71924100 @default.
• W1999489097 hasIssue "3" @default.
• W1999489097 hasLocation W19994890971 @default.
• W1999489097 hasOpenAccess W1999489097 @default.
• W1999489097 hasPrimaryLocation W19994890971 @default.
• W1999489097 hasRelatedWork W1530301808 @default.
• W1999489097 hasRelatedWork W1980245127 @default.
• W1999489097 hasRelatedWork W2091104967 @default.
• W1999489097 hasRelatedWork W2106003470 @default.
• W1999489097 hasRelatedWork W2114185421 @default.
• W1999489097 hasRelatedWork W2140855177 @default.
• W1999489097 hasRelatedWork W2400504790 @default.
• W1999489097 hasRelatedWork W2433835599 @default.
• W1999489097 hasRelatedWork W3133825612 @default.
• W1999489097 hasRelatedWork W2552340109 @default.
• W1999489097 hasVolume "69" @default.
• W1999489097 isParatext "false" @default.
• W1999489097 isRetracted "false" @default.
• W1999489097 magId "1999489097" @default.
• W1999489097 workType "article" @default.